Table 1.

Baseline characteristics of patients with LMS with and without ctDNA evaluation.

	Patients
	Without ctDNA evaluation	With ctDNA evaluation
Characteristic	N = 120	N = 98	P
Age at diagnosis, years
Median (range)	57.2 (33–81)	59.6 (28–83)	0.08
Sex
Male	37 (31%)	35 (35.7%)	0.45
Female	83 (69%)	63 (64.3%)
Primary tumor location
Extremity	13 (10.8%)	18 (18.4%)	0.11
Other	107 (89.2%)	80 (81.6%)
Extent of disease
Locally advanced	6 (5%)	3 (3.1%)	0.52
Distant metastatic	114 (95%)	95 (96.9%)
Grade at entry
Low/intermediate grade	49 (41%)	29 (30%)	0.09
High grade	71 (59%)	69 (70%)
Previous radiotherapy
No	88 (73.3%)	71 (72.4%)	0.88
Yes	32 (26.7%)	27 (25.6%)
Stage
I	7 (5.8%)	4 (4.1%)	0.72
II	30 (25%)	20 (20.4%)
III	41 (34.2%)	33 (33.7%)
IV	40 (33.3%)	39 (39.8%)
Unknown	2 (1.7%)	2 (2%)
Previous adjuvant/neoadjuvant
Yes	14 (11.7%)	9 (9.2%)	0.36
No	106 (88.3%)	89 (90.8%)
No. of sites at entry
≥5	42 (35%)	53 (54.1%)	0.005
<5	78 (65%)	45 (45.9%)
Best response
CR	1 (0.8%)	0	0.53
PR	21 (17.5%)	23 (23.5%)
SD	73 (61%)	55 (56.1%)
PD	16 (13.3%)	15 (15.3%)
NE	9 (8%)	5 (5.1%)

Abbreviations: CR, complete response; NE, non-evaluable; PD, progressive disease; PR, partial response; SD, stable disease.